舉報評價

abx ABX464

具體成交價以合同協議為準

公司名稱 MedChemExpress LLC
品牌 MedChemExpress (MCE)
型號 abx
產地
廠商性質 生產廠家
更新時間 2019/6/26 9:15:25
訪問次數 666

產品標簽

abx abx 464 abx464 abx-464

在線交流發送詢價查看電話同類產品

聯系我們時請說明是化工儀器網上看到的信息，謝謝!

索取相關資料

公司介紹 主營產品

MedChemExpress (MCE) 專注于為科學家提供高品質的生物活性小分子化合物，化合物庫及各類試劑盒，總部位于美國新澤西。
•   MedChemExpress (MCE) 產品作用于 20 多個熱門信號通路及研究領域的300多個細分靶點，擁有 10000 特異性抑制劑、激動劑，以及 50 活性化合物篩選庫；
•   我們堅持對所有產品進行嚴格質檢，確保產品的高品質和高純度；
•   MedChemExpress (MCE) 產品已被數萬名科學家信賴，并被大量top文獻和*引用；
•   我們擁有專業的技術團隊追蹤前沿科研進展，不斷豐富各個靶點的特異性產品，堅持做 “您身邊的抑制劑大師”；
•   MedChemExpress (MCE) 與眾多藥企和科研機構保持深度合作；
•   大量產品有中國庫存，工作日 16:00 前訂單確保當日發貨，次日送達。
MCE 中國站：www.MedChemExpress.cn

Hotline: 400-820-3792
Tel: 021-58955995
Email: sales@MedChemExpress.cn
Tech Support: 021-58950656

MedChemExpress - Inhibitors Agonists

MedChemExpress - Screening Libraries

MedChemExpress - Top Publications Citing Use of MCE

展開

抑制劑，調節劑，API，天然產物，各種類型化合物庫

詳細信息 在線詢價

供貨周期	現貨	規格	10 mM * 1 mL；1 mg；5 mg；10 mg；25 mg；50 mg
貨號	HY-100870	應用領域	生物產業

ABX464

產品活性：ABX464 是一種有效的抗 HIV 劑。ABX464 作用于受刺激的外周血單個核細胞 (PBMCs)，抑制 HIV-1 復制，IC₅₀ 為 0.1 μM 至 0.5 μM。

研究領域：Anti-infection

作用靶點：HIV

In Vitro: ABX464 inhibits HIV-1 production in PBMC- and macrophages-infected cells. ABX464 has a strong inhibitory effect for all HIV-1 subtypes tested including subtype B, C and recombinant viruses. ABX464 also very efficiently inhibits the replication of viral strains harbouring mutations that confer resistance to different therapeutic agents in vitro. While the antiviral drug 3TC is not highly active on K65R and M184V mutant strains, both strains are inhibited by ABX464. To generalize the effect of ABX464 on HIV-1 replication in other primary cells, cells are treated with between 0.01 μM up to 30 μM concentrations of ABX464 and p24 antigen levels are monitored in culture supernatants over a 12 days period. ABX464 efficiently blocks virus replication in a dose-dependent manner with an IC₅₀ ranging between 0.1 μM and 1 μM.

In Vivo: Humanized mice reconstituted with human lymphoid cells provide rapid, reliable, reproducible experimental systems for testing the efficacy of ABX464 in vivo. In the initial setting, SCID mice are reconstituted with PBMCs and then infected with the HIV-1 strain JR-CSF. Mice are treated twice a day (b.i.d) for 15 days by oral gavage with 20 mg/kg of ABX464. Measures of viral RNA show that the oral treatment with ABX464 is able to significantly reduce the viral load over a period of 15 days of treatment. FACS analysis of blood samples show that treatment with ABX464 prevents depletion of CD4⁺ cells following infection of reconstituted mice and thereby restores the CD8⁺/CD4⁺ ratio back to that of non-infected mice.